Exclusive: Here's How Much OpenAI Spends On Inference And Its MSFT Revenue Share

In a Better Offline exclusive, Ed Zitron reveals how much OpenAI spent on inference in 2024 and 2025, as well as how much it paid Microsoft as part of its 20% revenue share. Inference costs are much higher - and implied revenues much lower - than previously reported. (Free) Newsletter: https://www.wheresyoured.at/oai_docs/ The Information - OpenAI’s First Half Results: $4.3 Billion in Sales, $2.5 Billion Cash Burn - https://www.theinformation.com/articles/openais-first-half-results-4-3-billion-sales-2-5-billion-cash-burn?rc=kz8jh3 The Information (reference to $6bn inference spend) - http://theinformation.com/articles/openai-forecasts-revenue-topping-125-billion-2029-agents-new-products-gain?rc=kz8jh3 Want to support me? Get $10 off a year’s subscription to my premium newsletter: https://edzitronswheresyouredatghostio.outpost.pub/public/promo-subscription/w08jbm4jwg it would mean a lot! YOU CAN NOW BUY BETTER OFFLINE MERCH! Go to https://cottonbureau.com/people/better-offline and use code FREE99 for free shipping on orders of $99 or more. --- LINKS: https://www.tinyurl.com/betterofflinelinks Newsletter: https://www.wheresyoured.at/ Reddit: https://www.reddit.com/r/BetterOffline/ Discord: chat.wheresyoured.at https://discord.com/invite/QUUQUP9szv Ed's Socials: https://twitter.com/edzitron https://www.instagram.com/edzitron https://bsky.app/profile/edzitron.com https://www.threads.net/@edzitron Email Me: [email protected] mailto:[email protected] See omnystudio.com/listener https://omnystudio.com/listener for privacy information.

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:00Speaker 00

  This is an iHeart Podcast. Guaranteed Human. OnDeck is built to back small businesses like yours. Whether you're buying equipment, expanding your team, or bridging cash flow gaps, OnDeck's loans up to $400,000 help make it happen fast. Rated A+ by the Better Business Bureau and earning thousands of five-star TrustPilot reviews, OnDeck delivers funding you can count on. Apply in minutes at ondeck.com. Depending on certain loan attributes, your business loan may be issued by OnDeck or Celtic Bank. OnDeck does not lend in North Dakota. All loans and amounts subject to lender approval.

• 0:38Ed Zitron?

  Hello and welcome to a very special episode of Better Offline. I'm of course your host Ed Zitron.

• 0:51Ed Zitron?

  For years, I've been hunting down the core details behind OpenAI's costs and revenues, and today I'm going to bring you some of them. A lot of what I say today is going to be reflected in my newsletter, which I'll link to in the notes. Based on documents viewed by my newsletter, I'm able to report OpenAI's inference spend on Microsoft Azure in addition to its payments to Microsoft as part of its 20% revenue share agreement, which was reported in October 2024 by The Information. In simple terms, that last bit means that Microsoft receives 20% of OpenAI's revenue in addition to whatever it spends on GPUs and servers. As a reminder, inference is the process through which a model creates an output, which I'll be reminding you of a few times because it's actually kind of important. Now, a few notes.

• 1:33Ed Zitron?

  I don't have OpenAI's training spend, nor do I have information on the entire extent of OpenAI's revenues, as it appears that Microsoft shares some percentage of its revenue from Bing, as well as 20% of the revenue Microsoft receives from selling OpenAI's models on Azure. What I do have, as I've mentioned, is its inference spend. And if you're new to this, like I said, this means all the computations OpenAI does when processing requests sent to its services like ChatGPT and Sora. Now, before publishing, I asked a Financial Times reporter to help corroborate some of the data in the documents. They reached out to Microsoft and OpenAI, who both declined to comment. Now, the following will be a lot of numbers, and it might be easier for you to read them. However, I'm going to try and make things as easy and clear as possible, because the

• 2:16Ed Zitron?

  documents I've seen call into question what we actually knew about OpenAI's business and the sustainability of said business. To keep things simple, all the years in this piece are calendar years. Microsoft has fiscal years, I'm not going to play that game, it's impossible to follow along with, nobody thinks this way. Anyway, now we've done that, let's get to it. According to the documents viewed by my newsletter, OpenAI spent $5.02 billion on inference alone with Microsoft Azure in the first half of calendar year 2025. This is a pattern that has continued through the end of September 2025, by which point OpenAI had spent $8.67 billion just on inference.

• 2:56Ed Zitron?

  OpenAI's inference costs have risen consistently over the past 18 months, too. For example, OpenAI spent $3.76 billion on inference in 2024, meaning that OpenAI has already more than doubled its inference costs in just the first nine months of 2025. These costs are dramatic and significantly higher than has been previously reported. According to the information, OpenAI's computer run models, which I understand to mean inference, was $2 billion in 2024. Additionally, an April 2025 piece from the information stated that OpenAI's inference costs for 2025 would be around $6 billion, or roughly $2 billion less than OpenAI appears to have spent through the end of September.

• 3:38Ed Zitron?

  I want to be clear as well, I'm just reporting what these documents have said, this is not a statement about the information, they do great reporting. But, then there's the issue of the revenue share. As I've previously stated, the following numbers are based on the revenue share paid to Microsoft as part of its deal with OpenAI, where it gives Microsoft 20% of its revenues. According to the documents, Microsoft received $493.8 million in revenue share payments in 2024 from OpenAI, implying revenues for 2024 for OpenAI of at least $2.469 billion, or around $1.23 billion less than the $3.7 billion number that's been previously reported in multiple outlets.

• 4:20Ed Zitron?

  Similarly, for the first half of 2025, Microsoft received $454.7 million as part of its revenue share agreement, implying OpenAI's revenues for that six-month period were at least $2.273 billion, or around $2 billion less than the $4.3 billion previously reported for that period. Through September, Microsoft's revenue share payments totaled $865.8 million, implying OpenAI's revenues are at least $4.329 billion through the end of Q3 2025. To be clear, and I'm gonna say this, Microsoft also pays OpenAI a cut of Bing's revenues under certain circumstances I could not confirm, as well as a cut of about 20% of all OpenAI models sold through Azure.

• 5:05Ed Zitron?

  Just to be clear, Microsoft is the only party that can sell OpenAI's models other than OpenAI. I don't have the details on those payments, like I said, but I'm skeptical that they can account for the massive difference between those numbers that have been leaked and the ones in the documents in question. I do not know nor will I speculate on why these differences are so distinct. What was important about today was getting you these numbers and shedding light on the differences I see between the story told about OpenAI and the reality of its spend and potential revenues. You've also probably noticed that this podcast has a bit of a different tone to the usual. No insults, no jokes, haven't called anyone clammy, haven't even said a swear word for the first time in maybe 100 episodes. The reason's simple: these numbers are serious and seriously different to those reported.

• 5:49Ed Zitron?

  OpenAI's costs are dramatically higher than previously reported and thought, and based on the extrapolations from Microsoft's revenue share, its implied revenues are also seemingly dramatically lower than we knew. The ramifications of these numbers are severe. OpenAI's inference costs are incredibly high, absorbing any and all revenues and seemingly scaling with every increase in ChatGPT's user numbers. As revenue goes up, so does their inference costs. Conversely, if these implied revenues are indicative of the larger financial picture, OpenAI is not as successful a company as we previously believed. In any case, the reality of the AI bubble is becoming clearer. Inference, the process of creating outputs for a model, appears to be an incredibly

• 6:31Ed Zitron?

  burdensome cost, and if these implied revenues are any indicator, the actual business of selling generative AI services and models doesn't really seem to be as good a business as we thought either. It's all looking a little bleak out there. I don't want to editorialize too much because I want this information to sit on its own self, but it's strange being here. It's strange getting these numbers and seeing them myself. And I have to wonder how things work out from here. I truthfully have no idea, but I do know I'll be happy to do this every week and I will tell you what happens now. These numbers allow us to kind of see the real picture of the AI bubble.

• 7:13Ed Zitron?

  And I have to wonder what other companies look like now that I've seen these numbers. Email me, contact me, ezitron.76 on Signal if you ever want to tell me anything, if you ever want to show me anything. I'm always interested to hear and I'm honored to do this.

• 7:36Speaker 02

  Snoring, gasping for air during sleep, daytime sleepiness. I'm Shaquille O'Neal and this shouldn't be anybody's experience. Asher, Doctor about Zepbound Trisepotide, the first and only FDA-approved prescription medicine for moderate to severe obstructive sleep apnea in adults with obesity.

• 7:52Speaker 03

  Zepbound is a prescription medicine used with a reduced calorie diet and increased physical activity to help adults with moderate to severe obstructive sleep apnea, OSA, and obesity to improve their OSA. Zepbound is approved as a 2.5, 5, 7.5, 10, 12.5, or 15-milligram injection. Zepbound contains trisepotide and should not be used with other trisepotide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Don't chew needles or pens, or reuse needles. Don't take if allergic to it, or if you or someone in your family had medullary thyroid cancer, or if you've had multiple endocrine neoplasia syndrome type 2. Tell your doctor if you get a lump or swelling in your neck. Stop Zepbound and call your doctor if you have severe stomach pain or a serious allergic

• 8:37Speaker 03

  reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes before scheduled procedures with anesthesia. If you're nursing, pregnant, plant-to-be, or taking birth control pills. Taking Zepbound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea, and vomiting, which can cause dehydration and worsen kidney problems.

• 8:59Speaker 02

  Talk to your doctor. Call 1-800-545-5979 or visit zepbound.lily.com.

• 9:07Speaker 04

  Empower is all about helping you invest well so you can go out and live a little. And their free Empower Personal Dashboard shows you your full financial life in one place. You'll be able to see your net worth, monitor budgets, analyze your portfolio, set retirement goals, and more. Whether you're saving for something big, want to treat yourself, friends, or family, or meet long-term goals, Empower helps you see where you stand. You've worked hard for your money, and Empower can help you make the most of it. Download the Empower Personal Dashboard or visit empower.com. Not an Empower client paid or sponsored. This is an iHeart Podcast. Guaranteed human.